Decals – We Check Because We Care, Ventura County Health Care Agency Patients, family members and prescribers all benefit from messaging starting at the clinic door. Contact usfor more information about materials.
The Controlled Substance Utilization Review and Evaluation System (CURES) contains information about whether other clinicians have prescribed controlled substances to your patient. This type of information can help prescribers make informed decisions and avoid duplicate or additive types of medications from being provided to patients. The mandate to consult CURES prior to prescribing, ordering, administering, or furnishing a Schedule II-IV controlled substance became effective on October 2, 2018.
The following evidence-based interventions also lower overdose death rates:
Avoid co-prescribing an opioid and a benzodiazepine. Nationally the number of opioid deaths involving benzodiazepine is increasing annually.
Minimize opioid prescribing for acute pain. According to the Centers for Disease Control and Prevention (CDC), clinicians should avoid opioids, and when necessary, start with the lowest effective dose of immediate-release opioids. Three days or less will often be sufficient. Opioids should not be considered first-line or routine therapy for chronic pain.
Taper opioids to safer doses. The CDC recommends that for patients already on long-term high dose opioid therapy, taper to a dose that is lower than 50 milligrams of morphine equivalent. Slow opioid tapers as well as pauses in the taper may be needed for long-term users.
Avoid “the 90-day cliff.” The CDC recommends opioids should be discontinued if benefits do not outweigh risks
The CDC recommends prescribing naloxone to patients on higher than 50 milligrams of morphine equivalents daily. The mandate to offer a prescription for naloxone to a patient at high risk of overdose became effective January 1, 2019.